Pertuzumab: as the comparator
33 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.
- Comparative Study of QL1209 and Perjeta® in Healthy Male ParticipantsNot yet recruitingNCT07861139Phase 1Report a problem
- SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNot yet recruitingNCT07856303Phase 2Report a problem
- Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11Not yet recruitingNCT07776132Phase 1Report a problem
- A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast CancerNot yet recruitingNCT07601620Phase 1Report a problem
- A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNot yet recruitingNCT07545044Phase 2Report a problem
- Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®Not yet recruitingNCT07495930Phase 1Report a problem
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerRecruitingNCT07441460Phase 3Report a problem
- ctDNA in HER2+ EBC Neoadjuvant TreatmentRecruitingNCT07335081Phase 2Report a problem
- Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.Not yet recruitingNCT07136974Phase 2Report a problem
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingNCT07102381Phase 2Report a problem
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingNCT07043725Phase 3Report a problem
- A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerRecruitingNCT07003074Phase 3Report a problem
- A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseRecruitingNCT06643585Phase 3Report a problem
- T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerNot yet recruitingNCT06548178Phase 2Report a problem
- Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialRecruitingNCT06278870Phase 3Report a problem
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingNCT05900206Phase 2Report a problem
- Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.RecruitingNCT05838066Phase 3Report a problem
- NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerRecruitingNCT05704829Phase 2Report a problem
- Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingNCT05638594Phase 2Report a problem
- Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast CancerNot yet recruitingNCT05430347Phase 2Report a problem
- TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)Not yet recruitingNCT04760431Phase 2Report a problem
- Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCompletedNCT02073487Phase 2Results postedReport a problem
- A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast CancerActive, not recruitingNCT07386938Phase 3Report a problem
- A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast CancerActive, not recruitingNCT07196774Phase 3Report a problem
- A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast CancerActive, not recruitingNCT06747338Phase 3Report a problem
- A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast CancerWithdrawnNCT05474690Phase 3Report a problem
- A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsActive, not recruitingNCT05426486Phase 2/3Report a problem
- Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single InjectionCompletedNCT05323981Phase 1Report a problem
- Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2Report a problem
- Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast CancerStatus unknownNCT04717531Phase 2Report a problem
- Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.CompletedNCT04629846Phase 3Report a problem
- Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast CancerStatus unknownNCT04246502Phase 2Report a problem
- Neoadjuvant Response-guided Treatment of HER2 Positive Breast CancerActive, not recruitingNCT02568839Phase 2/3Report a problem